



RECEIVED  
TECH CENTER 1600/2900  
99 FEB 19 AM 10:15

PATENT  
P-2821RI

GP1634

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APPLICANT(S): James G. Nadeau et al.

FEB 12 1999

SERIAL NO.: 09/082,247

GROUP: 1634 MATRIX CUSTOMER  
SERVICE CENTER

FILING DATE: May 20, 1998

EXAMINER: S. Houtteman

FOR: DETECTION OF NUCLEIC ACID AMPLIFICATION

RESPONSE TO PROTEST

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY STATEMENT

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON,  
D.C. 20231

ON: February 2, 1999  
(DATE OF DEPOSIT)

BY: Mary Lou Kittren  
(NAME)

Mary Lou Kittren 2-2-99  
(SIGNATURE) (DATE)

This document is filed to address issues raised in a Protest filed on December 31, 1998 (the "Protest") against the present reissue application.

The Protest was filed by Robin L. Teskin of Burns, Doane, Swecker & Mathis, L.L.P. (the "Protestor") on behalf of Georgetown University Medical Center ("GUMC"). (See, Exhibit A as evidence of GUMC participation). The Protest raises issues of: (1) claim invalidity under 35 U.S.C. §112, first paragraph (enablement); (2) claim invalidation under 35 U.S.C. §102 (anticipation); and (3) deceptive intention by the undersigned, the Applicants and the Assignee (hereinafter, collectively, the "Reissue Parties") of the present reissue application.

The Reissue Parties respectfully submit that the claims of the present reissue application are fully enabled, and are not anticipated by prior art. Specific comments regarding the enablement and anticipation issues are being deferred until such comment is requested by the Examiner. However, because the deceptive intention issue is necessarily based on the Protestor's inference of intent, this Response will refute the allegation of deceptive intention. It is stated